Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals: A Randomized Clinical Trial.

JAMA network open - 1 Mar 2022

Nadkarni Girish N, Fei Kezhen, Ramos Michelle A, Hauser Diane, Bagiella Emilia, Ellis Stephen B, Sanderson Saskia, Scott Stuart A, Sabin Tatiana, Madden Ebony, Cooper Richard, Pollak Martin, Calman Neil, Bottinger Erwin P, Horowitz Carol R

Abstract excerpt

IMPORTANCE: Risk variants in the apolipoprotein L1 (APOL1 [OMIM 603743]) gene on chromosome 22 are common in individuals of West African ancestry and confer increased risk of kidney failure for people with African ancestry and hypertension. Whether disclosing APOL1 genetic testing results to patients of African ancestry and their clinicians affects blood pressure, kidney disease screening, or patient behaviors is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoprotein L1
Share to Black or African American

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disclosure

Share to Genetic Predisposition to Disease

Share to Genetic Testing

Share to Health Personnel

Share to Hypertension

Share to Renal Insufficiency, Chronic

Source

Open in PubMed Open full text

Identifiers

PMID: 35244702
DOI: 10.1001/jamanetworkopen.2022.1048
PMCID: PMC8897752

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals: A Randomized Clinical Trial.PMID 35244702Read ↗

Genetic Testing for APOL1 in Adults With Hypertension: The GUARDD-US Randomized Clinical Trial.Semantic proximity Read ↗

Determining the effects and challenges of incorporating genetic testing into primary care management of hypertensive patients with African ancestry.Semantic proximity Read ↗

Race, Genomics and Chronic Disease: What Patients with African Ancestry Have to SaySemantic proximity Read ↗

Prevalence of Mendelian kidney disease among patients with high-risk<i>APOL1</i>genotypes undergoing commercial genetic testing in the United StatesSemantic proximity Read ↗

Stakeholder Perspectives on Returning Nonactionable Apolipoprotein L1 (APOL1) Genetic Results to African American Research Participants.Semantic proximity Read ↗

Communicating Risk Alleles in Kidney Genes: Lessons from APOL1 and New Discoveries of Risk Alleles.Semantic proximity Read ↗

APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Semantic proximity Read ↗

The Electronic Medical Records and Genomics study: Design and analytic framework for assessing the impact of genome-informed risk assessments.Semantic proximity Read ↗

Effect of Genetic African Ancestry on eGFR and Kidney Disease.Semantic proximity Read ↗

An ancestry-matched Mendelian randomisation analysis of kidney function and heart failure subtypes in African ancestry populationsSemantic proximity Read ↗

Perceptions regarding genetic testing in populations at risk for nephropathy.Semantic proximity Read ↗

Outcomes of a Randomized Controlled Trial of Genomic Counseling for Patients Receiving Personalized and Actionable Complex Disease Reports.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.